Hi Kevin,
You conducted a really thorough and detailed analysis, taking into account almost all the elements in the study designs. Our scores are close, but we seem to take different approach in the scoring. For example, for the Organization in the Amanyire et al., we both have a score of 3, but our arguments are different.
I noticed in Christine analysis that our arguments were similar, but the scores are different.
I am curious about the inter rater reliability of this instrument this tool is. A very useful tool, though.
Kadiatou raises a really good point about the inter-rater reliability. (I'm actually wondering if the intra-rater reliability is very good either.)
In reading everyone's responses, it reminds me how much your context and understanding can influence how you rate the studies, especially for the outcome.
Hey Kevin, Thanks for your thoughts. I had a different take on the outcome measurement, mostly that the Aminyire outcome was very practical (I think I gave it a 5). They were evaluating a tool to streamline implementation, not to measure virologic suppression (which was the outcome that was evaluated in the Rosen study). The impact of early ART initiation on virologic outcomes and mortality has already been evaluated in prior studies.